ID Source | ID |
---|---|
PubMed CID | 8344 |
CHEMBL ID | 1302251 |
SCHEMBL ID | 186285 |
MeSH ID | M0109900 |
Synonym |
---|
117-82-8 |
dimethoxyethyl phthalate |
wln: 1o2ovr bvo2o1 |
2-methoxyethyl phthalate |
phthalic acid, di(methoxyethyl) ester |
nsc2147 |
1, bis(2-methoxyethyl) ester |
kesscoflex mcp |
phthalic acid, bis(2-methoxyethyl) ester |
methyl glycol phthalate |
bis(methoxyethyl) phthalate |
bis(2-methoxyethyl) phthalate |
dimethylglycol phthalate |
nsc-2147 |
dimethoxy ethyl phthalate |
1,2-benzenedicarboxylic acid, bis(2-methoxyethyl) ester |
di(2-methoxyethyl)phthalate |
NCGC00090803-01 |
di-(2-methoxyethyl)ester kyseliny ftalove [czech] |
dimethyl cellosolve phthalate |
nsc 2147 |
ai3-01366 (usda) |
einecs 204-212-6 |
di-(2-methoxyethyl) ester kyseliny ftalove [czech] |
kodaflex dmep |
ai3-01366 |
di(2-methoxyethyl) phthalate |
hsdb 5016 |
methox |
brn 2056929 |
di-(2-methoxyethyl)phthalate |
bis(methylglycol) phthalate, technical, >=90% (gc) |
bis(2-methoxyethyl) benzene-1,2-dicarboxylate |
P0965 |
phthalic acid bis(2-methoxyethyl) ester |
NCGC00090803-02 |
4-09-00-03241 (beilstein handbook reference) |
di-(2-methoxyethyl) ester kyseliny ftalove |
unii-68w8xuo221 |
1,2-benzenedicarboxylic acid, 1,2-bis(2-methoxyethyl) ester |
68w8xuo221 , |
di-(2-methoxyethyl)ester kyseliny ftalove |
dtxsid8025094 , |
dtxcid805094 |
tox21_303033 |
cas-117-82-8 |
NCGC00256966-01 |
tox21_201857 |
NCGC00259406-01 |
CHEMBL1302251 |
AKOS015888206 |
SCHEMBL186285 |
bis (methylglycol) phthalate |
di(methoxyethyl)phthalate |
phthalic acid, di(2-methoxyethyl)ester |
HSUIVCLOAAJSRE-UHFFFAOYSA-N |
reomol p |
methoxy ethyl phthalate |
benzenedicarboxylic acid, bis(2-methoxyethyl) ester |
bis(methylglycol) phthalate |
J-003671 |
bis(2-methoxyethyl)phthalate |
mfcd00042842 |
bis(methylglycol) phthalate, analytical standard |
phthalic acid, bis-methylglycol ester |
phthalic acid bis(2-methoxyethyl)ester |
Q15632774 |
Dimethoxyethyl phthalate (DMEP) is an environmental endocrine disruptor.
Excerpt | Reference | Relevance |
---|---|---|
"Dimethoxyethyl phthalate (DMEP) is an environmental endocrine disruptor. " | ( DMEP induces mitochondrial damage regulated by inhibiting Nrf2 and SIRT1/PGC-1α signaling pathways in HepG2 cells. Cai, Y; Han, W; Liu, C; Liu, H; Zhu, S, 2021) | 2.06 |
Excerpt | Relevance | Reference |
---|---|---|
" On an equimolar dosage basis, DMEP, 2-ME, and MAA were equally potent, which is consistent with the hypothesis." | ( Teratogenicity of dimethoxyethyl phthalate and its metabolites methoxyethanol and methoxyacetic acid in the rat. Randall, JL; Ritter, EJ; Ritter, JM; Scott, WJ, 1985) | 0.6 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 1.5849 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 61.5038 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.1995 | 0.0013 | 18.0743 | 39.8107 | AID926; AID938 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 34.5861 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 10.0000 | 0.0054 | 28.0263 | 1,258.9301 | AID720659 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 21.9393 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 6 (60.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (20.00) | 29.6817 |
2010's | 1 (10.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.33) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |